FDA approves Ascendis Pharma’s weekly Yuviwel for paediatric dwarfism

BioMarin’s Voxzogo (vosoritide) won FDA approval in paediatric achondroplasia in November 2021 and secured a label extension ...
Fierce Pharma

Ascendis gains more altitude with FDA approval for dwarfism drug Yuviwel

Ascendis Pharma is spiraling upward by way of its TransCon platform. | Ascendis Pharma is spiraling upward by way of its ...
MedPage Today

Once-Weekly Treatment Approved for Achondroplasia in Kids

It joins the CNP analog vosoritide (Voxzogo), a once-daily injection, as the only treatments approved for achondroplasia.
BioPharma Dive

Ascendis wins FDA approval of dwarfism drug

Yuviwel, a once-weekly injection, will now compete for market share with BioMarin’s lucrative daily shot Voxzogo.
Medical Dialogues

FDA Approves Navepegritide for Achondroplasia in Children

The FDA has approved navepegritide (Yuviwel), developed by Ascendis Pharma, for children aged 2 years and older with ...

Ascendis wins US approval for therapy for children with dwarfism

By Sahil Pandey and Puyaan Singh Feb 27 (Reuters) - The U.S. Food and Drug Administration on Friday approved Ascendis Pharma's once-weekly therapy for children with a rare genetic disorder that causes ...
News-Medical.Net on MSN

New mouse model uncovers achondroplasia's cellular growth plate dysregulation

Achondroplasia, also known as short-limb dwarfism, is associated with neurological symptoms and complications due to ...
FierceBiotech

Sanofi will drop phase 2 dwarfism drug as part of rare disease clear-out

Sanofi has halted work on a phase 2 candidate for a rare growth disorder as part of a pipeline clear-out that saw the French pharma discontinue two other rare disease assets and one of its mRNA flu ...